Keybanc Maintains Overweight on Castle Biosciences, Raises Price Target to $40

Benzinga · 2d ago
Keybanc analyst Paul Knight maintains Castle Biosciences (NASDAQ:CSTL) with a Overweight and raises the price target from $35 to $40.